Skip to content

Perturbation Training Reduces Falls in People With Alzheimer's Disease (AD)

Motor Learning of Fall Resistant Skills From Laboratory-induced Falling Among People With Mild Alzheimer's Disease

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05205980
Acronym
STAD
Enrollment
30
Registered
2022-01-25
Start date
2023-04-28
Completion date
2026-10-30
Last updated
2026-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Disease

Brief summary

This study will examine the overall capacity of people with Alzheimer's disease learning fall-resistant skills from perturbation training.

Detailed description

Falls can cause injury and death in older adults. Those with Alzheimer's disease are at an even higher fall risk. Our goal is to test if people with mild Alzheimer's disease can learn fall prevention skills from the exposure to large-scale perturbations on a treadmill. Two groups with mild Alzheimer's disease will be enrolled. One group will attend a perturbation training session while the other group receives no training. Groups will then be exposed to perturbations on the ground immediately and three or six months after the training. Over six months after the training, daily-living falls will be tracked for both groups. The falls following the perturbations in the lab and daily-living all-cause falls will be compared between groups to test our specific aims: 1) to test if people with Alzheimer's disease can adapt to large-scale external perturbations and learn fall resistant motor skills; 2) to inspect whether people with Alzheimer's disease can retain motor skills learned in Aim 1; and 3) to determine if people with Alzheimer's disease can generalize fall resistant skills to different contexts (treadmill to overground, inside the lab to outside the lab).

Interventions

Participants will experience repeated perturbations mixed with non-perturbed trials on the treadmill with the protection by a harness.

Sponsors

Georgia State University
Lead SponsorOTHER
National Institutes of Health (NIH)
CollaboratorNIH
Alzheimer's Association
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Masking description

The assessor will be blinded to the group assignment of each participant.

Eligibility

Sex/Gender
ALL
Age
65 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Participants must be at least 65 years old; * Participants have a clinical diagnosis of probable AD; * Participants can read and understand English; * Participants must be able to walk independently at least 25 feet; * Participants must be able to stand independently for at least 30 seconds; * Participants must have a Montreal Cognitive Assessment score of 11-21 or Mini Mental Status Examination score between 18 and 23.

Exclusion criteria

* Individuals have ever experienced perturbation training; * Individuals have hypotension or uncontrolled hypertension; * Individuals exhibit osteoporosis; * Participants suffer from coexisting psychiatric disorders, or other neurological conditions, or injuries, etc.

Design outcomes

Primary

MeasureTime frameDescription
Lab-induced faller rate6 monthsThe outcome of each perturbation trial will be determined as a fall if the peak load cell force exceeds 30% of the body weight. The load cell records the force applied to the human body by the safety harness system after a perturbation. The lab-induced faller rate will be calculated as the ratio of the number of fallers to the number of participants within each group.

Secondary

MeasureTime frameDescription
Dynamic stability6 monthsDynamic stability will be calculated for each perturbation trial based on the kinematics of the body's center of mass relative to the base of support.
Number of prospective fall incident6 monthsThe number of all cause falls in daily-living activities after the training session will be recorded for each participant.

Countries

United States

Contacts

CONTACTFeng Yang, PhD
fyang@gsu.edu404-413-8357
PRINCIPAL_INVESTIGATORFeng Yang, PhD

Georgia State University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026